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Abstract
Cardiovascular disease (CVD) is the most important cause of premature death and disability globally. Much is
known of the main aetiological risk factors, including elevated blood pressure, dyslipidaemia and smoking, with a
raft of additional risks of increasing prevalence, such as obesity and diabetes. Furthermore, some of the most secure
evidence-based management strategies in healthcare relate to interventions that modify risk. Yet major gaps remain
in the implementation of such evidence, summarized in international guideline recommendations. Some of this
gap relates to knowledge deficits amongst clinicians, but also to continued uncertainties over interpretation of the
evidence base and areas where data are less available. This article collection in BMC Medicine seeks to offer
reflections in each of these areas of uncertainty, spanning issues of better diagnosis, areas of controversy and
glimpses of potentially potent future interventions in the prevention of CVD.
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Editorial
Cardiovascular disease (CVD) remains the leading cause
of global morbidity and mortality [1]. The risk factors of
abnormal lipids, smoking, hypertension, diabetes, ab-
dominal obesity, poor diet and irregular physical exercise
account for more than 90 % of the CVD risk in
epidemiological studies [2].
The commonest risk factor is hypertension, with a glo-
bal prevalence estimated at 26.4 % (972 million adults)
in 2000 and a predicted rise of 60 % to a total of 1.56
billion adults (29.2 %) by 2025 [3]. A major predictor for
coronary heart disease (CHD) and stroke [4, 5], inter-
national guidelines highlight the management of hyper-
tension [6, 7] based on huge clinical outcome trial
datasets [8], which show that a net blood pressure (BP)
reduction of 10–12 mmHg systolic BP and 5–6 mmHg
diastolic BP reduces stroke incidence by 38 % and CHD
by 16 % [9]. In absolute terms, treating 1000 patients in
four 5-year CVD risk groups observed in the placebo
arms of trials (5-year risks of <11 %, 11–15 %, 15–21 %
and >21 %) with BP-lowering treatment for 5 years
would prevent 14 (95 % CI: 8–21), 20 (95 % CI: 8–31),
24 (95 % CI: 8–40) and 38 (95 % CI: 16–61) cardiovascu-
lar events, respectively (P = 0.04 for trend) [9].
Interventions that lower low-density lipoprotein chol-
esterol (LDL-C) concentrations are also proven to sig-
nificantly reduce the incidence of CHD and other major
vascular events in a wide range of individuals. A meta-
analysis of 14 statin trials showed that for every 40 mg/dL
(1 mmol/L) decrease in LDL-C, it led to a 21 % decrease
in CHD risk after 1 year of treatment [10]. These data
were incorporated into clinical guidance, such as the
American College of Cardiology/American Heart
Association (ACC/AHA) [11] and National Cholesterol
Education Program (NCEP) Adult Treatment Panel (ATP)
III guidelines [12] in the US; the Joint Task Force of the
European Society of Cardiology and Other Societies on
Cardiovascular Disease Prevention in Clinical Practice
guidelines in Europe [13]; and the National Institute for
Health and Care Excellence (NICE) in the UK, which all
recognise the importance of dyslipidaemia, as well as
hypertension and smoking, as the main risk factors for
CVD. They also provide practical tools (Framingham,
Systematic Coronary Risk Evaluation (SCORE) and QRISK
10-year CVD risk algorithms, respectively) to assist short-
term risk estimation in individuals without prior CVD,
although there remain many barriers to guideline imple-
mentation in routine clinical practice [14].
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However, despite this huge evidence base on the
aetiology of CVDs and their treatment options, many
questions still remain unanswered. Some of these are
considered in this special article collection in BMC
Medicine, including critical reviews on diagnosing
hypertension [15], the potential of PCSK9 antibodies
[16], an entirely new class of LDL-C modifiers devel-
oped from basic concept to phase III trials in less
than a decade, and the evidence for smoking reduc-
tion interventions [17].
In the near future, there will also be an upcoming
forum debate on the relative impact of statins on vas-
cular disease — over 20 years after their introduction
and now one of the most prescribed drugs in the
world, there remains much debate on these agents.
The article collection will also present the updated
guidance on stroke prevention in atrial fibrillation
(SPAF) which, alongside detection and management
of hypertension, is the most important strategy to
prevent stroke. Atrial fibrillation (AF) is the common-
est cardiac arrhythmia, with about 1–2 % of the gen-
eral population estimated to be affected [18]. It is a
particularly common disorder in older people, with
over 5 % over the age of 65 years suffering from AF
and around 10 % of people over the age of 75 years
[19, 20], with the prevalence predicted to rise [21, 22].
Patients with AF are at an almost five-fold higher risk
of stroke compared to age-matched individuals with
normal sinus rhythm [23], as well as at a twice as
high risk of all-cause mortality and heart failure.
About 20 % of all ischaemic strokes are attributable
to embolism as a result of AF [24]. Not only do pa-
tients with AF have more strokes, they also develop
more recurrent strokes, more severe strokes, regard-
less of age [25], and are more likely to be left with
long-term disability and require long-term care [26].
It is a very important topic for patients and for
healthcare system payers.
Accompanied by peer-reviewed research papers
[27–30], this article collection, Prevention of cardio-
vascular diseases, should be of interest to all BMC
Medicine readers.
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